CMENEUTRAL

P/E Ratio

18.7x

Updated 103h ago

Sector Performance

34th percentile

CME

18.7x

Sector Median

24.7x

Sector Avg

36.0x

📊

Deep Analysis

The current P/E Ratio of 18.7x means that for every dollar of earnings per share, investors are paying $18.70 for CME stock — a common measure of how expensive or cheap a stock is relative to its profits.

This is below the sector median of 24.5x, putting CME in the 34th percentile among its sector peers, meaning it is cheaper than about two-thirds of comparable companies. The year-over-year change is not available, but the quarter-over-quarter change shows a decline of 10.4%, moving from 20.9x in the prior quarter to the current 18.7x. A below-median P/E combined with a falling trend can signal a potential value opportunity if the earnings outlook is stable, but it also raises risk if the decline reflects worsening fundamentals rather than a temporary dip. This metric supports the overall NEUTRAL verdict — the low relative valuation suggests limited downside, yet the downward quarterly shift warrants caution, balancing neither a strong buy nor sell signal.

Frequently Asked Questions

What does the P/E Ratio tell investors about CME?

Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.

How is the P/E Ratio calculated?

P/E Ratio is calculated as: Price / EPS.

Who are CME's closest peers by P/E Ratio?

The closest peers by P/E Ratio include: VICI (9.1x), OMF (9.0x), JACK (8.5x), GIS (8.4x), FIS (8.4x).

The Formula

Price / EPS

Why It Matters

Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.

Advertisement

Master CME's Valuation

Get the complete institutional research report covering all fundamental and technical metrics.

View full CME research report

Free account — no credit card

CME

18.7x

Sector Median

24.7x

Sector Avg

36.0x

How CME's P/E Ratio compares to sector peers.

Not financial advice. Research tool only. Data may be delayed.